Aetiologically linked to HPV infection, malignancies of the anal canal have substantially increased in incidence over the last 20 years. Although most anal squamous cell carcinomas (SCCs) respond well to chemoradiotherapy, about 30% of patients experience a poor outcome, for undetermined reasons. Despite cumulative efforts for discovering independent predictors of overall survival, both nodal status and tumour size are still the only reliable factors predicting patient outcome. Recent efforts have revealed that the biology of HPV-related lesions in the cervix is strongly linked to the originally infected cell population. To address the hypothesis that topography also influences both gene expression profile and behaviour of anal (pre)neoplastic lesions, we correlated both proteomic signatures and clinicopathological features of tumours arising from two distinct portions of the anal canal: the lower part (squamous zone) and the more proximal anal transitional zone. Although microdissected cancer cells appeared indistinguishable by morphology (squamous phenotype), unsupervised clustering analysis of the whole proteome significantly highlighted the heterogeneity that exists within anal canal tumours. More importantly, two region-specific subtypes of SCC were revealed. The expression profile (sensitivity/specificity) of several selected biomarkers (keratin filaments) further confirmed the subclassification of anal (pre)cancers based on their cellular origin. Less commonly detected compared to their counterparts located in the squamous mucosa, SCCs originating in the transitional zone more frequently displayed a poor or basaloid differentiation, and were significantly correlated with reduced disease-free and overall survivals. Taken together, we present direct evidence that anal canal SCC comprises two distinct entities with different cells of origin, proteomic signatures, and survival rates. This study forms the basis for a dualistic classification of anal carcinoma, with implications for management, outcome expectations, and possibly therapy.
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have identified some carcinogenic types of human papillomaviruses (HPVs), mainly HPV16 genotype, as the leading cause of most cases (∼90%) of anal squamous cell carcinoma (SCC) and its precursors, which are designated as anal intraepithelial neoplasia (AIN) [6] [7] [8] [9] [10] [11] . Although data on the prevalence of AIN in the general population are limited [12] , anal malignant transformation is presumed to progress slowly, similarly to other HPV-related tumours in the genital tract. Commonly misdiagnosed as a benign abnormality (e.g. haemorrhoids) because of non-specific symptoms [13] , invasive anal SCC is traditionally treated with radiotherapy alone or in combination with chemotherapy. These treatment options are tailored to the tumour stage and HIV status [14, 15] .
The anal canal is about 4 cm in length and extends from the anorectal ring to the anal margin. The upper third, located above the dentate line, is covered by a columnar epithelium. The area immediately adjacent to the squamocolumnar junction is called the anal transitional zone and is composed of one to three layers of immature squamous cells beneath columnar cells (transitional 'urothelium-like' epithelium). The more distal or caudal part of the canal is lined by a pluristratified squamous epithelium which merges gradually with the skin (with hair follicles and sweat glands) at the anal margin [16] .
Although most anal SCCs respond well to chemoradiotherapy, a subgroup of patients has a poor prognosis, for unclear reasons [17] . Several molecular factors, such as p53, p21, Bcl-2 or desmocollin-1, have been proposed as independent predictors for both local control and/or overall survival [18, 19] , but there is a lack of concordance between reported results, due to the limited number of patients analysed in most studies [17, 18] . Therefore, despite these cumulative efforts, both nodal status and tumour size are still the only reliable factors predicting the outcome in patients with anal canal SCC.
In the past, the nomenclature of anal canal cancers has been confusing and there were attempts to classify neoplastic lesions into three groups: large cell keratinizing, large cell non-keratinizing, and cloacogenic. Because of the lack of location specificity and a poor inter-observer diagnostic reproducibility, all of these tumour variants were lumped into the 'epidermoid family'. Accordingly, the new edition of the WHO classification system now recommends systematic use of the generic term 'SCC'.
In the present multi-institutional study, we tested the hypothesis that anal SCC encompassed more than one tumour type as a function of cell population initially infected by HPV.
Materials and methods

Tissue specimens and clinical data retrieval
A total of 254 anal canal specimens were retrieved from the archives of University Hospital Centre of Liège (Belgium), Citadelle Regional Hospital (Liège), Jules Bordet Institute (Brussels, Belgium), University of Arkansas for Medical Sciences (Little Rock, AR, USA), and Brigham and Women's Hospital (Boston, MA, USA) for the period between 2001 and 2015. The protocol was approved by the ethics committees of the respective institutions. These samples included 154 primary invasive SCCs, 69 dysplastic lesions [19 low-grade AIN (AIN1) and 50 high-grade AIN (AIN2/3)], and 31 normal anal canal tissues (haemorrhoidectomies). All (pre)neoplastic lesions were re-examined by senior histopathologists to confirm the diagnosis and categorize both AIN and early-stage SCC into two groups according to their micro-anatomical location/origin (anal transition zone versus squamous zone of the anal canal). This separation was based on both the location of the original site of tumour invasion and the non-cancerous histological structures surrounding the neoplastic lesions. The origin of late-stage neoplasms (especially T3-T4 tumours measuring more than 5 cm) was impossible to determine precisely by microscopic examination. Tumour differentiation was also determined (supplementary material, Figure S1 ). Lesions strictly observed in the anal margin (defined by the presence of skin-associated structures such as hair follicles and apocrine/sweat glands) were not included in the study. Clinicopathological information was collected for all patients treated for invasive SCC. Patient demographics, tumour stage (according to the American Joint Committee on Cancer), HIV status, treatment details (surgery, radiotherapy, and/or chemotherapy), and follow-up data were obtained from medical records. Tumour specimens associated with incomplete clinicopathological data were excluded.
Laser capture microdissection and sample processing Sections (6 μm thick) of SCC specimens were deparaffinized and rehydrated in graded alcohols. For laser capture microdissection, tissue sections were dried and ∼5000 cancer cells were captured onto high recovery tube caps using a Leica LMD7000 system (Leica Microsystems, Wetzlar, Germany). Quantification of neoplastic cells was previously performed on one serial section [haematoxylin and eosin (H&E) staining] by computerized image analysis (Mesurim Pro Software, Amiens, France). The experimental procedure for sample processing has been recently described [20] . The detailed protocol is available in the supplementary material, Supplementary materials and methods.
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equipped with a nanospray source. MaxQuant software (version 1.5.2.8) was used to analyse raw mass spectrometric files [21] . Perseus software (version 1.5.0.15) was used to perform further downstream statistical and bioinformatic analyses of the MaxQuant processing results (principal component analysis, volcano plot, heatmap, sample-to-sample comparisons, and hierarchical clustering). The detailed procedure is given in the supplementary material, Supplementary materials and methods. The mass spectrometry proteomics data have been deposited at the ProteomeXchange Consortium [22] via the PRIDE partner repository [23] with the dataset identifier PXD004859.
Immunohistochemistry
Immunohistochemical analyses were performed as previously described [24] [25] [26] . The primary antibodies used in this study are listed in the supplementary material, Supplementary materials and methods. The specificity of the antibodies was determined by western blot (supplementary material, Figure S2 ) as well as directly by immunohistochemistry [by using a tissue specimen containing the target molecule in its known location (positive control)]. Mouse and rabbit control IgGs (Santa Cruz Biotechnology, Santa Cruz, CA, USA) were used as negative controls.
Immunofluorescence
The immunofluorescence protocol has been described previously [27] . The primary antibodies were similar to those used for immunohistochemistry. Anti-mouse Alexa 488 and anti-rabbit 633 (Invitrogen, Carlsbad, CA, USA) were used as secondary antibodies. Pictures were acquired with a Leica SP5 confocal microscope (GIGA-Flow Cytometry and Cell Imaging Platform, University of Liège).
Immunohistochemical assessment
All immunolabelled tissues were evaluated by independent investigators (experienced histopathologists). p16 ink4 immunostaining was scored as positive when anal (pre)neoplastic lesions displayed a strong/uniform basal or full-thickness immunoreactivity. The proliferative index (nuclear Ki67 staining) was calculated as the percentage of positively stained cells. This was stratified as follows: 0-5%, 6-25%, 26-50%, 51-75%, and > 75%. A similar scoring system was used to assess cytoplasmic keratin immunoreactivity.
HPV genotyping
Fourteen high-risk HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 , 66, and 68) were simultaneously detected using the Abbott RealTime High-Risk HPV test (Abbott, Wiesbaden, Germany). This assay, which also allows the partial genotyping of HPV16 and 18 from the other 12 carcinogenic genotypes, has been previously shown to be highly sensitive for HPV detection in formalin-fixed tissues [28] .
p53 gene mutation analysis Genomic DNA was extracted from SCC specimens (NucleoSpin DNA FFPE XS kit, Macherey-Nagel, Düren, Germany) and exons 4-8 of TP53 were amplified by polymerase chain reaction (PCR). According to the International Agency for Research on Cancer (IARC) database, more than 90% of all TP53 mutations detected in cancer are located in these five exons. The primer sequences used are listed in the supplementary material, Table S1 . PCR amplicons were then purified and sequenced based on the Sanger method using an ABI 3700 automated sequencer (Applied Biosystems, Foster City, CA, USA) (GIGA-Genomics platform, University of Liège).
Statistical analysis
Sensitivity, specificity, and positive/negative predictive values were calculated for each evaluated biomarker (cut-off score: > 75% positive cells). Test accuracy was also evaluated by receiver operating characteristic (ROC) curve analysis. The statistical difference between two groups of immunolabelled specimens was assessed by using a two-tailed Student's t-test. The comparisons of clinical data between independent groups were made by using Fisher's exact test or a χ 2 test. Overall survival (OS) was defined as the time from the date of registration/biopsy to the date of death (from any cause) or the date of the last follow-up visit. Disease-free survival (DFS) was calculated from the date of registration/biopsy to the date of local or distant recurrence. OS and DFS estimations were performed using the Kaplan-Meier method. SAS statistical (version 9.3) or GraphPad Prism 5 software packages were used for statistical analyses and differences were considered statistically significant when p < 0.05.
Results
Mass spectrometric analyses reveal two region-specific subtypes of anal canal neoplasms
Histologically, the anal canal is formed by an inner (upper) columnar zone; an intermediate portion of a few millimetres long, lined by a transitional epithelium; and a lower part covered by a pluristratified squamous epithelium ( Figure 1A ). Microscopic analysis of tissue specimens revealed that anal canal (pre)neoplastic lesions can be divided into two groups based on their micro-anatomical location/origin. Transitional epithelium and/or glands are typically observed in the microenvironment of anal lesions arising from the transitional zone, while neoplasms located within the squamous zone of the anal canal are characterized by an uninterrupted pluristratified epithelium ( Figure 1A ). By laser capture microdissection, ten independent early-stage SCCs (T1 or T2, < 2.5 cm long) of each category were sampled. In order to avoid bias related to HPV status, all analysed cases were infected by HPV16 
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(single infection). The tiny laser-microdissected tissue pieces were subjected to an 'on-tissue' digestion. The complex peptide mixtures were separated by liquid chromatography, and proteomic analyses (MS/MS) were then conducted ( Figure 1B) . Although cancer cells were selected from distinct regions of the anal canal, they all displayed a squamous phenotype ( Figure 1B) . Significantly, principal component analysis (PCA) of the whole protein expression patterns revealed two region-specific subtypes of SCC (anal transitional zone versus squamous zone), while two-thirds (66.5%) of identified proteins were detected in both cancer groups ( Figure 1C, D) . On the basis of the values of intensity obtained from the proteins of the MassPREP protein digestion standard (MPDS) mix and their known quantities, ∼800 ng of proteins was obtained per sample (5000 cells). Combining the data from 20 samples using label-free quantification, a total of 35 013 unique peptides (38 109 in total) corresponding to 4465 proteins were identified (supplementary material, Table S2 ). Among those, 4462 were quantifiable. Out of these latter proteins, 2333 were detected in at least eight samples out of ten in at least one group. When a cut-off criterion (>2.0-fold change and p < 0.01) was used, 484 proteins were identified as differentially expressed in neoplastic lesions present within the anal transition zone, compared with their counterparts arising from the squamous mucosa of the anal canal ( Figure 1E , F and supplementary material, Table S3 ). Among these region-overexpressed proteins, we searched for enriched Gene Ontology terms and KEGG pathways (Fisher's exact test). Biological processes or protein families linked to desmosomes (enrichment factor 3.397, p < 0.001), keratin filaments (enrichment factor 3.309, p < 0.001), DNA replication [e.g. minichromosome maintenance (MCM) proteins; enrichment factor 3.209, p < 0.001], and cell cycle (enrichment factor 2.962, p < 0.001) were found to be notably enriched (supplementary material, Table S4 ).
Detection of region-specific/overexpressed proteins in (pre)neoplastic lesions and normal tissue specimens
The distinction between the two subtypes of anal canal SCC was underscored by examining global protein patterns as in the principal component analysis, as well as a selected set of region-overexpressed proteins (Figure 2A ). To validate some of these protein expression differences identified by mass spectrometry, we stained serial sections of early-stage SCC with antibodies against six different keratins (Krt). These were selected based on the already current use in diagnostic pathology of some of these molecules for determining tumour origins, the availability of specific antibodies, and the enrichment of keratin filaments highlighted by mass spectrometry. In agreement with our proteomic analyses, most SCCs (T1) observed in the lower part of the anal canal displayed a diffuse positivity (>75% positive cells) for Krt6B (14/14, 100%), Krt14 (10/14, 71.4%), and Krt16 (10/14, 71.4%), whereas antibodies to Krt7, Krt8, and Krt19 showed immunoreactivity largely restricted to neoplasms arising from the anal transition zone (Figures 2B, 3C , and Table 1 ). In order to extend our immunohistochemical analysis, 69 preneoplastic lesions (AIN) and 31 normal anal canal specimens were also stained with the 'region-specific' antibodies. With the exception of five cases, all AIN displayed a diffuse p16 ink4a staining pattern in keeping with the presence of a carcinogenic HPV infection. Similar to the results collected from cancer cases, diffuse Krt7, Krt8, and Krt19 immunoreactivities were only detected in precursor lesions located in the anal transitional zone ( Figure 3A , C and Table 1 ). In contrast to preneoplastic lesions observed in the anal squamous mucosa (which extensively express Krt6B, Krt14, and Krt16), only a low percentage of transitional zone-located lesions stain for these three antigens in more than 75% of cells ( Figure 3C and Table 1 ). Further confirming the subclassification of anal (pre)cancers based on their cellular origin, the expression of these keratin filaments perfectly demarcated the different parts of the normal anal canal. Indeed, Krt6B, Krt14, and Krt16 proteins were only detected in the squamous area, whereas Krt7, Krt8, and Krt19 were specifically expressed in the transitional zone. Representative examples are shown in Figure 3B , and detailed results are presented in Figure 3C . We next determined the specificity, sensitivity, and positive/negative predictive values of these six keratins for determining the origin of anal (pre)neoplastic lesions. Given the 'black or white' expression pattern displayed by these proteins in most cases ( Figure 3C ), a single cut-off score (>75% positive cells) assuring an excellent inter-observer agreement was applied. Although all of these identified proteins proved to be highly sensitive, Krt7 and Krt19 were the most reliable and sensitive biomarkers (negativity: squamous zone; positivity: transitional zone) ( Table 1 ). The area under the ROC curve, determining the test accuracy, further confirmed these results (highest for Krt7 and Krt19: 97%) ( Figure 3D ). The detection of these keratin filaments was therefore used for segregating the late-stage (T2-T4) anal tumours according to their origin. The use of two biomarkers further guaranteed the accuracy of the results.
Clinicopathological features of invasive SCC of the anal canal according to micro-anatomical origin
One hundred and fifty-four patients with histologically confirmed invasive SCC of the anal canal, with complete medical records, and who were treated between January 2001 and June 2015, were enrolled in the present study. Tumours arising from the squamous mucosa were approximately twice as frequent (101 versus 53; 66% versus 34%) than neoplasms originating in the anal transitional zone. Patient characteristics according to tumour origin (determined by the keratin expression pattern) are listed in Table 2 Although the large majority (93%) of SCCs were HPV-positive, 11 tumours were HPV-negative. Interestingly, all of the latter lesions were observed in the lower part of the anal canal (p = 0.044) and three of the 11 (27%) displayed p16 immunoreactivity. The HPV status was undetermined in five patients (3.2%) because of insufficient extracted DNA. Significantly, a larger proportion of tumours arising from the transitional zone exhibited a high proliferative index (>75% of Ki67-positive cells) (p < 0.001). Tumour differentiation also correlated with micro-anatomical location. Well-differentiated SCC, not observed in the anal transitional zone, accounted for approximately one third (35%) of all neoplasms observed in the squamous mucosa. In contrast, tumours located within the transitional microenvironment displayed more frequently a poor (15%) or basaloid (40%) differentiation. These differences were highly significant (p < 0.001).
Tumour origin predicts both disease-free and overall survival in patients with HPV-positive anal canal SCC Figure 4 . The prognostic values of risk factors associated with DFS and OS are detailed in Figure 4E . The difference in outcome between the two groups became statistically significant when the HPV status was taken into account and, consequently, HPV-negative tumours (all located in the squamous zone) were considered as a different entity ( Figure 4C,  D) . Indeed, DFS at 5 years was 56.2% for patients with SCC originating in the transitional zone, as opposed to 85.3% for HPV-positive squamous mucosa-located cancers [hazard ratio (HR) = 2.76; p = 0.020]. Similarly, 5-year OS was 55.1% versus 80.4% (HR = 2.82; p = 0.021). Interestingly, tumour origin (determined by the expression of keratin filaments) was shown to be a better predictor than both nodal status and tumour size ( Figure 4E ). HPV-negative SCC was associated with both poor DFS and OS ( Figure 4C -E). However, its incidence is increasing in the United States and worldwide, and the age at diagnosis is decreasing [2, 3] . In the present study, we report that both the natural history and the phenotype of anal canal SCC strongly depend on their cellular origin (squamous zone versus anal transition zone). Indeed, mass spectrometry analysis revealed two distinct subtypes of SCC and these results were further confirmed by immunophenotypic parameters collected in a large cohort of anal (pre)neoplastic lesions. Our data also highlighted the utility of a quantitative proteomic approach for the global identification of expressed proteins in paraffin-embedded tissue specimens [29, 30] . Millions of tissue blocks are archived each year in pathology departments all around the world. Given the poor quality of mRNAs extracted from these samples, transcriptomic analyses are extremely challenging and usually provide disappointing results. Here, we were able to identify a large number of proteins from 5000 microdissected cells and to use some of them as biomarkers with diagnostic and prognostic value. Compared with some other approaches previously described for microdissected or restricted paraffin-embedded tissue pieces [31] [32] [33] , the experimental procedure used in the present study allows the identification of higher numbers of proteins with strict data processing parameters. In addition, by analysing replicates on the same tissue area from serial sections, a high reproducibility was demonstrated (supplementary material, Figure S3 and Table S5 ).
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Regarding the six keratin filaments selected, both Krt7 and Krt19 proved to be highly specific and sensitive for determining the origin of anal (pre)neoplastic lesions. Although keratin filament reorganization has been reported in advanced tumours of various origins (in particular when cancer cells underwent an epithelial to mesenchymal transition) [34] , the association between keratin expression and (pre)cancer location was remarkably consistent in context with cell of origin. Indeed, the 'black or white' expression pattern observed in both normal anal tissues and neoplastic lesions, whatever the stage, strongly argues against the acquisition or loss of these two keratin filaments as a function of tumour progression/dedifferentiation. Furthermore, these results confirm the increasing use of keratins in the context of several organs for correlating tumour origin with patient treatment/follow-up [35] . The specific expression of both Krt7 and Krt8 in the anal transitional zone is also consistent with the recent detection of these proteins within or in close proximity to other squamocolumnar junctions (oesophago-gastric and endo-ectocervical junctions) [36, 37] . The concept of two forms of anal canal SCC as a function of tumour origin is novel and adds another dimension to the prior dichotomy centred on HPV status (positive versus negative). The latter distinction is a relatively minor issue overall, given that most anal (pre)neoplastic lesions are aetiologically linked to HPV infection. Similar to many studies conducted in the United States and Europe [6, 7] , carcinogenic HPV genotypes were detected in most (92.6%) of the anal invasive SCCs analysed in the present study, with HPV16 being much the most prevalent type (92%). Although excellent concordance between HPV DNA status and p16 ink4 immunoreactivity was observed, three out of 11 HPV-negative cases (27%) strongly expressed this surrogate biomarker for HPV infection. This phenomenon of false-positive results with the use of p16 ink4 immunostaining has been extensively reported in the context of head and neck cancers [38] . Although less frequently detected, similar data were also recently pointed out in anal SCC [9, 10] . In our study, it was not surprising that HPV-unrelated SCCs were associated with an unfavourable outcome. The unexpected finding was that all of these tumours were observed in the lower (caudal) portion of the anal canal. The prognostic value of HPV status is well documented in patients with oropharyngeal SCC [39] .
In agreement with our data, three recent studies focusing on anal canal cancer demonstrated a significant association between p16 negativity and unfavourable prognosis [8] [9] [10] . The poor prognosis associated with HPV-negative lesions is likely to be multifactorial. Higher numbers of activating mutations [40] , hypoxic areas [41] , and disruptive p53 mutations [42] were recently identified in non-infected head and neck SCCs compared with their HPV-induced counterparts.
Interestingly, we examined p53 mutations in all the patients with HPV-negative SCC and in 20 randomly selected HPV-positive anal canal tumours, and as expected, HPV infection was inversely correlated with p53 mutation. While p53 mutations were uncommon in HPV-infected SCCs whatever their origin (4/20, 20%), seven out of 11 (63.6%) HPV-negative SCCs displayed a mutated p53 gene (supplementary material, Table S6 ). The latter results were further confirmed by analysing the percentage of cells displaying strong nuclear p53 immunoreactivity (supplementary material, Figure S4 ).
The finding of greatest interest in this study was the link between putative cell of origin and tumour outcome in HPV-positive SCC. We found that tumour origin is an independent predictor for both disease relapse and reduced OS. In addition, this latter parameter had a better predictive value than both nodal status and tumour size. As detailed in Table 2 , these shorter survival rates are not likely to be explained by differences in tumour stage, age at diagnosis or treatment. Similarly, immunodeficient patients were excluded for DFS and OS analysis. Although still subject to further analysis, several parameters could explain the variations in outcome according to tumour origin. Importantly, we reported marked differences between transitional zone-located SCCs and their counterparts observed in the squamous mucosa at the level of tumour differentiation. Indeed, tumours displaying a poor or basaloid differentiation represented a larger proportion within the group originating in the transitional zone (54.7% versus 12.9%). These results are in agreement with a previous descriptive study showing that keratin profiles do not precisely segregate anal tumours based on their maturation subtypes [43] . In addition, our observations confirm the historical observations that non-keratinizing tumours (an obsolete term used in the former WHO classification) arise more frequently in the proximal part of the anal canal. Poorly differentiated cancers have been extensively shown to have a worse prognosis in the context of various organs (e.g. breast, lung, prostate) [44] [45] [46] . Similarly, both oropharyngeal and lung SCCs displaying a basaloid profile were associated with low survival rates attributable to a higher propensity to metastasize [47, 48] . Interestingly, Das et al also reported an increased risk of distant metastasis in patients with basaloid anal cancer treated with definitive chemoradiation [49] .
In the context of site of origin, the mass spectrometry analysis revealed additional and potentially important information with implications for tumour biology and potentially therapy. Strong overexpression of several members of the MCM family was found in SCCs that originated from the transitional zone microenvironment (Figure 2A ). Involved in DNA replication in dividing cells and not expressed in quiescent/differentiated cells, MCM proteins were proposed as novel proliferative markers. In support of this, Ki67 and MCM 4/5 expression correlated closely in both normal and anal canal cancer tissues, and co-immunolocalizations were extremely frequently observed (supplementary material, Figure S5 ). However, MCM 4/5 immunoreactivity was largely more intense in cancer (especially those arising from the transitional zone) compared with normal anal epithelia (supplementary material, Figure S5 ). The role of MCM proteins in carcinogenesis is slowly emerging as a concept, and consistent with our results, several recent studies have shown that their overexpression is an indicator of aggressiveness in a wide range of cancers (e.g. breast, brain, ovary) [50] [51] [52] . The potential value of these proteins for the detection of anal (pre)neoplastic lesions in cytology samples was also highlighted [53] . Interestingly, recent data demonstrated the involvement of the MCM protein family in DNA repair/chromatin remodelling following DNA damage [54] . Therefore, in an age of targeted therapy, MCM proteins were proposed as promising candidates for anti-cancer drug development, allowing enhancement of the sensitivity of high-risk disease to chemoradiotherapy.
Taken together, our data highlight both the heterogeneity among anal canal tumours and the prognostic significance of tumour origin in patients treated for HPV-positive SCC. Although further studies need to be performed, proteomic analysis strongly supports the existence of two anal canal SCC subtypes which could be treated and/or managed and followed up differently according to their cellular origin. This latter parameter could be easily determined in future studies by analysing the expression of one or several biomarkers which have been identified and validated in the present work. Table S1 . PCR primers used for TP53 amplification (exons 4-8) Table S2 . List of all the human proteins identified (combining data from 20 samples) Table S3 . List of region-specific/overexpressed proteins Table S4 . Enriched biological processes in region-specific/overexpressed proteins 
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